The European Medicines Agency has approved Akili’s ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD), which uses a video game to treat the underlying cause
Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm's generic version of Neos’ ADHD drug Cotempla XR-OD
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the
